teva pharmaceuticals introduces the first generic glp-1 for weight loss FDA Approves Version of Liraglutide Injection, a Generic Version of Victoza Now
Description
This means they have not been formally assessed for safety, efficacy, or quality by the New Zealand's medicines regulator (6)
The most common side effects include nausea, gastrointestinal discomfort, changes in appetite, and feeling full more quickly
Yes, significantly
It's a region involved in emotion and the reward system
Metabolic: Euglycemic DKA The risk of euglycemic DKA is very uncommon, but its a clinically important and real complication to be aware of in patients using GLP-1 agonists
